Close Menu

This article has been updated from a previous version to include clarifying information from Veracyte about the developers of the gene signature.

NEW YORK – Veracyte said on Thursday that it has signed an exclusive licensing agreement with Yale University for a genomic test to predict disease progression in patients with idiopathic pulmonary fibrosis (IPF).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.